



Clinical trial results:

A Phase III, Randomized, Observer Blind, Multicenter Study to Evaluate the Safety and Immunogenicity of Repeated Exposure to an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV), Administered to Subjects Previously Vaccinated in Trial V118_05

Summary

| | |
|--------------------------|-----------------|
| EudraCT number | 2014-002599-95 |
| Trial protocol | FI |
| Global end of trial date | 13 January 2016 |

Results information

| | |
|--------------------------------|-------------------|
| Result version number | v1 (current) |
| This version publication date | 27 September 2017 |
| First version publication date | 27 September 2017 |

Trial information

Trial identification

| | |
|-----------------------|-----------|
| Sponsor protocol code | V118_05E1 |
|-----------------------|-----------|

Additional study identifiers

| | |
|------------------------------------|-------------|
| ISRCTN number | - |
| ClinicalTrials.gov id (NCT number) | NCT02255409 |
| WHO universal trial number (UTN) | - |

Notes:

Sponsors

| | |
|------------------------------|---|
| Sponsor organisation name | Seqirus UK Limited |
| Sponsor organisation address | The Point, 29 Market Street, Maidenhead, United Kingdom, SL6 8AA |
| Public contact | Clinical Trial Disclosure Manager, Seqirus, Seqirus.Clinicaltrials@seqirus.com |
| Scientific contact | Clinical Trial Disclosure Manager, Seqirus, Seqirus.Clinicaltrials@seqirus.com |

Notes:

Paediatric regulatory details

| | |
|--|---------------------|
| Is trial part of an agreed paediatric investigation plan (PIP) | Yes |
| EMA paediatric investigation plan number(s) | EMA-001715-PIP01-14 |
| Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? | No |
| Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? | No |

Notes:

Results analysis stage

| | |
|--|-----------------|
| Analysis stage | Final |
| Date of interim/final analysis | 31 January 2017 |
| Is this the analysis of the primary completion data? | No |

| | |
|----------------------------------|-----------------|
| Global end of trial reached? | Yes |
| Global end of trial date | 13 January 2016 |
| Was the trial ended prematurely? | No |

Notes:

General information about the trial

Main objective of the trial:

Primary Immunogenicity Objective: To evaluate the antibody responses to homologous (CBER criteria) influenza strains post vaccination with aQIV or a non-adjuvanted comparator influenza vaccine in children previously vaccinated in parent trial V118_05.

Primary Safety Objective: To evaluate the safety of revaccination of aQIV or nonadjuvanted comparator vaccine in children previously vaccinated in parent trial V118_05

Protection of trial subjects:

This clinical study was designed and was to be implemented and reported in accordance with the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Harmonized Tripartite Guidelines for Good Clinical Practice (GCP), with applicable local regulations including European Directive 2001/20/EC, US Code of Federal Regulations (CFR) Title 21, and Japanese Ministry of Health, Labor, and Welfare, sponsor codes on protection of human rights, and with the ethical principles laid down in the Declaration of Helsinki European Council 2001, US CFR, ICH 1997).

Background therapy: -

Evidence for comparator: -

| | |
|---|-------------------|
| Actual start date of recruitment | 18 September 2014 |
| Long term follow-up planned | Yes |
| Long term follow-up rationale | Safety |
| Long term follow-up duration | 12 Months |
| Independent data monitoring committee (IDMC) involvement? | No |

Notes:

Population of trial subjects

Subjects enrolled per country

| | |
|--------------------------------------|--------------------|
| Country: Number of subjects enrolled | Finland: 100 |
| Country: Number of subjects enrolled | United States: 507 |
| Worldwide total number of subjects | 607 |
| EEA total number of subjects | 100 |

Notes:

Subjects enrolled per age group

| | |
|---|---|
| In utero | 0 |
| Preterm newborn - gestational age < 37 wk | 0 |
| Newborns (0-27 days) | 0 |

| | |
|--|-----|
| Infants and toddlers (28 days-23 months) | 101 |
| Children (2-11 years) | 506 |
| Adolescents (12-17 years) | 0 |
| Adults (18-64 years) | 0 |
| From 65 to 84 years | 0 |
| 85 years and over | 0 |

Subject disposition

Recruitment

Recruitment details:

Subjects were enrolled from 30 sites in 2 countries

Pre-assignment

Screening details:

All enrolled subjects were included in the trial

Period 1

| | |
|------------------------------|---|
| Period 1 title | Overall Study (overall period) |
| Is this the baseline period? | Yes |
| Allocation method | Randomised - controlled |
| Blinding used | Double blind |
| Roles blinded | Subject, Investigator, Monitor, Data analyst, Carer, Assessor |

Arms

| | |
|------------------------------|------|
| Are arms mutually exclusive? | Yes |
| Arm title | aQIV |

Arm description:

Subjects approximately ≥ 12 months to 7 years of age who had received aQIV in the parent study V118_05 received aQIV in the present study V118_05E1.

| | |
|--|--|
| Arm type | Experimental |
| Investigational medicinal product name | Adjuvanted Quadrivalent Influenza Vaccine (aQIV) -surface antigen, inactivated, adjuvanted with MF59 |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

IM/0.5ml (0.25 mL for subjects <36 months)

| | |
|------------------|----------------|
| Arm title | Comparator QIV |
|------------------|----------------|

Arm description:

Subjects approximately ≥ 12 months to 7 years of age who had received TIV/QIV in the parent study V118_05 received QIV in the present study V118_05E1.

| | |
|--|--|
| Arm type | Experimental |
| Investigational medicinal product name | Inactivated Quadrivalent Influenza Virus Vaccine |
| Investigational medicinal product code | |
| Other name | |
| Pharmaceutical forms | Suspension for injection |
| Routes of administration | Intramuscular use |

Dosage and administration details:

IM/0.5ml (0.25 mL for subjects <36 months)

| Number of subjects in period 1 | aQIV | Comparator QIV |
|---------------------------------------|------|----------------|
| Started | 318 | 289 |
| Completed | 304 | 258 |
| Not completed | 14 | 31 |
| Consent withdrawn by subject | 1 | 5 |
| Lost to follow-up | 10 | 19 |
| Administrative reason | 3 | 7 |

Baseline characteristics

Reporting groups

| | |
|---|----------------|
| Reporting group title | aQIV |
| Reporting group description: | |
| Subjects approximately ≥12 months to 7 years of age who had received aQIV in the parent study V118_05 received aQIV in the present study V118_05E1. | |
| Reporting group title | Comparator QIV |
| Reporting group description: | |
| Subjects approximately ≥12 months to 7 years of age who had received TIV/QIV in the parent study V118_05 received QIV in the present study V118_05E1. | |

| Reporting group values | aQIV | Comparator QIV | Total |
|--|---------|----------------|-------|
| Number of subjects | 318 | 289 | 607 |
| Age categorical | | | |
| Units: Subjects | | | |
| In utero | 0 | 0 | 0 |
| Preterm newborn infants (gestational age < 37 wks) | 0 | 0 | 0 |
| Newborns (0-27 days) | 0 | 0 | 0 |
| Infants and toddlers (28 days-23 months) | 51 | 50 | 101 |
| Children (2-11 years) | 267 | 239 | 506 |
| Adolescents (12-17 years) | 0 | 0 | 0 |
| Adults (18-64 years) | 0 | 0 | 0 |
| From 65-84 years | 0 | 0 | 0 |
| 85 years and over | 0 | 0 | 0 |
| Age continuous | | | |
| Units: months | | | |
| arithmetic mean | 44.7 | 42 | |
| standard deviation | ± 19.04 | ± 17.47 | - |
| Gender categorical | | | |
| Units: Subjects | | | |
| Female | 171 | 155 | 326 |
| Male | 147 | 134 | 281 |

End points

End points reporting groups

| | |
|---|----------------------------------|
| Reporting group title | aQIV |
| Reporting group description: Subjects approximately ≥ 12 months to 7 years of age who had received aQIV in the parent study V118_05 received aQIV in the present study V118_05E1. | |
| Reporting group title | Comparator QIV |
| Reporting group description: Subjects approximately ≥ 12 months to 7 years of age who had received TIV/QIV in the parent study V118_05 received QIV in the present study V118_05E1. | |
| Subject analysis set title | Full Analysis Set - Homologous |
| Subject analysis set type | Full analysis |
| Subject analysis set description: All subjects in the Enrolled Set, who received a study vaccination and provided evaluable serum samples against vaccine strains for both before (baseline) and after vaccination. | |
| Subject analysis set title | Full Analysis Set - Heterologous |
| Subject analysis set type | Full analysis |
| Subject analysis set description: All subjects in the Enrolled Set, who received a study vaccination and provided evaluable serum samples against heterologous strains for both before (baseline) and after vaccination. | |

Primary: Immunogenicity Endpoint: Percentage of subjects achieving seroconversion - Homologous Strains (Day 22)

| | |
|---|---|
| End point title | Immunogenicity Endpoint: Percentage of subjects achieving seroconversion - Homologous Strains (Day 22) ^[1] |
| End point description: Antibody responses assessed in terms of percentage of subjects achieving seroconversion at 21 days after vaccination against vaccine strains. Seroconversion is defined as HI $\geq 1:40$ for subjects negative at baseline (ie, HI titer $< 1:10$); or a minimum 4-fold increase in HI titer for subjects positive at baseline (ie, HI titer HI $\geq 1:10$). The immunogenicity responses of the study vaccines were evaluated following measurements established by the current CBER criteria for the pediatric population. The CBER criteria were met if the lower bound of the 2-sided 95% CI for the percent of subjects achieving SC for HI antibody met or exceeded 40% | |
| End point type | Primary |
| End point timeframe: 21 days after vaccination | |
| Notes: [1] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point. Justification: The analysis of the primary endpoint was descriptive. | |

| End point values | aQIV | Comparator QIV | | |
|----------------------------------|---------------------|---------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 302 | 257 | | |
| Units: percentage of subjects | | | | |
| number (confidence interval 95%) | | | | |
| A/H1N1 | 57.9 (52.2 to 63.6) | 56.4 (50.1 to 62.6) | | |

| | | | | |
|------------|---------------------|---------------------|--|--|
| A/H3N2 | 50.7 (44.9 to 56.4) | 56.6 (50.3 to 62.8) | | |
| B/Yamagata | 73.5 (68.2 to 78.4) | 57.2 (50.9 to 63.3) | | |
| B/Victoria | 72.2 (66.8 to 77.2) | 58 (51.7 to 64.1) | | |

Statistical analyses

No statistical analyses for this end point

Primary: Immunogenicity Endpoint: Percentage of subjects achieving HI titer \geq 1:40 - Homologous Strains (Day 22)

| | |
|-----------------|---|
| End point title | Immunogenicity Endpoint: Percentage of subjects achieving HI titer \geq 1:40 - Homologous Strains (Day 22) ^[2] |
|-----------------|---|

End point description:

Antibody responses assessed in terms of percentage of subjects achieving HI titer \geq 1:40 at 21 days after vaccination against vaccine strains.

The immunogenicity responses of the study vaccines were evaluated following measurements established by the current CBER criteria for the pediatric population. The CBER criteria were met if the lower bound of the 2-sided 95% CI for the percent of subjects achieving an HI titer \geq 1:40 met or exceeded 70%.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

21 days after vaccination

Notes:

[2] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive.

| End point values | aQIV | Comparator QIV | | |
|----------------------------------|---------------------|--------------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 302 | 257 | | |
| Units: Percentage of subjects | | | | |
| number (confidence interval 95%) | | | | |
| A/H1N1 | 100 (98.8 to 100) | 99.6 (97.9 to 100) | | |
| A/H3N2 | 99.7 (98.2 to 100) | 100 (98.6 to 100) | | |
| B/Yamagata | 95.7 (92.8 to 97.7) | 81.3 (76 to 85.9) | | |
| B/Victoria | 98 (95.7 to 99.3) | 72 (66.1 to 77.4) | | |

Statistical analyses

No statistical analyses for this end point

Primary: Safety Endpoint: Subjects reporting SAEs, AEs leading to withdrawal from the study, new onset of chronic diseases (NOCD), adverse events of special interest

(AESI) and medically attended AEs

| | |
|-----------------|---|
| End point title | Safety Endpoint: Subjects reporting SAEs, AEs leading to withdrawal from the study, new onset of chronic diseases (NOCD), adverse events of special interest (AESI) and medically attended AEs ^[3] |
|-----------------|---|

End point description:

Safety was assessed in terms of number of subjects reporting SAEs, AEs leading to withdrawal, NOCDs, AESI and medically attended AEs.

| | |
|----------------|---------|
| End point type | Primary |
|----------------|---------|

End point timeframe:

Up to 12 months after vaccination

Notes:

[3] - No statistical analyses have been specified for this primary end point. It is expected there is at least one statistical analysis for each primary end point.

Justification: The analysis of the primary endpoint was descriptive.

| End point values | aQIV | Comparator QIV | | |
|--------------------------------|-----------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 317 | 288 | | |
| Units: Number of subjects | | | | |
| SAEs | 7 | 4 | | |
| At least possibly related SAEs | 0 | 0 | | |
| NOCDs | 13 | 7 | | |
| AESI | 1 | 1 | | |
| Medically attended AEs | 161 | 141 | | |
| AEs leading to withdrawal | 0 | 0 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Safety Endpoint: Subjects with solicited local and systemic AEs and other solicited data

| | |
|-----------------|--|
| End point title | Safety Endpoint: Subjects with solicited local and systemic AEs and other solicited data |
|-----------------|--|

End point description:

Safety was assessed in terms of percentage of subjects reporting solicited local and systemic adverse events following vaccination.

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

7 days following vaccination

| End point values | aQIV | Comparator QIV | | |
|-----------------------------|-----------------|-----------------|--|--|
| Subject group type | Reporting group | Reporting group | | |
| Number of subjects analysed | 317 | 288 | | |
| Units: number of subjects | | | | |
| Any | 202 | 148 | | |
| Local | 173 | 112 | | |
| Systemic | 127 | 80 | | |
| Other | 66 | 26 | | |

Statistical analyses

No statistical analyses for this end point

Secondary: Immunogenicity Endpoint: Geometric Mean Titers Ratios - Homologous Strains (Day 22)

| | |
|--------------------------------------|---|
| End point title | Immunogenicity Endpoint: Geometric Mean Titers Ratios - Homologous Strains (Day 22) |
| End point description: | |
| GMT Ratio: aQIV (GMT) over QIV (GMT) | |
| End point type | Secondary |
| End point timeframe: | |
| 21 days after vaccination | |

| End point values | Full Analysis Set - Homologous | | | |
|--|--------------------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 582 ^[4] | | | |
| Units: Titers | | | | |
| geometric mean (confidence interval 95%) | | | | |
| A/H1N1 | 1.48 (1.3 to 1.7) | | | |
| A/H3N2 | 1.34 (1.2 to 1.5) | | | |
| B/Yamagata | 1.75 (1.5 to 2) | | | |
| B/Victoria | 1.49 (1.2 to 1.8) | | | |

Notes:

[4] - aQIV N=309, QIV N=273

Statistical analyses

No statistical analyses for this end point

Secondary: Immunogenicity Endpoint: Geometric Mean Titers Ratios - Heterologous

Strains (Day 22)

| | |
|-----------------|---|
| End point title | Immunogenicity Endpoint: Geometric Mean Titers Ratios - Heterologous Strains (Day 22) |
|-----------------|---|

End point description:

GMT Ratio: aQIV (GMT) over QIV (GMT)

Heterologous strains tested: A/H3N2 is Influenza A H3N2 Hong Kong/2014 Ab; B/Yamagata is Influenza B/Phuket/2013 Ab

| | |
|----------------|-----------|
| End point type | Secondary |
|----------------|-----------|

End point timeframe:

21 days after vaccination

| End point values | Full Analysis Set - Heterologous | | | |
|--|----------------------------------|--|--|--|
| Subject group type | Subject analysis set | | | |
| Number of subjects analysed | 293 ^[5] | | | |
| Units: Titer ratios | | | | |
| geometric mean (confidence interval 95%) | | | | |
| A/H3N2 | 1.57 (1.3 to 1.9) | | | |
| B/Yamagata | 2.21 (1.8 to 2.7) | | | |

Notes:

[5] - aQIV N=155, QIV N=138

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Day 1 through Day366

Adverse event reporting additional description:

Solicited local and systemic AEs were reported from day 1 through day 7 after vaccination. All unsolicited AEs were captured through day 22. SAEs, AEs leading to withdrawal, NOCDs, AESIs were captured from day 1 through day 366

| | |
|-----------------|----------------|
| Assessment type | Non-systematic |
|-----------------|----------------|

Dictionary used

| | |
|-----------------|--------|
| Dictionary name | MedDRA |
|-----------------|--------|

| | |
|--------------------|------|
| Dictionary version | 19.1 |
|--------------------|------|

Reporting groups

| | |
|-----------------------|------|
| Reporting group title | aQIV |
|-----------------------|------|

Reporting group description:

Subjects approximately ≥12 months to 7 years of age who had received aQIV in the parent trial received aQIV in the present study.

| | |
|-----------------------|----------------|
| Reporting group title | Comparator QIV |
|-----------------------|----------------|

Reporting group description:

Subjects ≥12 months to 7 years of age who had received a comparator non adjuvanted TIV/QIV in the parent study V118_05 received a non adjuvanted QIV in the present study V118_05E1.

| Serious adverse events | aQIV | Comparator QIV | |
|---|-----------------|-----------------|--|
| Total subjects affected by serious adverse events | | | |
| subjects affected / exposed | 7 / 318 (2.20%) | 4 / 289 (1.38%) | |
| number of deaths (all causes) | 0 | 0 | |
| number of deaths resulting from adverse events | 0 | 0 | |
| Congenital, familial and genetic disorders | | | |
| Right ventricle outflow tract obstruction | | | |
| subjects affected / exposed | 1 / 318 (0.31%) | 0 / 289 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Blood and lymphatic system disorders | | | |
| Immune thrombocytopenic purpura | | | |
| subjects affected / exposed | 1 / 318 (0.31%) | 0 / 289 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Respiratory, thoracic and mediastinal disorders | | | |
| Asthma | | | |

| | | | |
|---|-----------------|-----------------|--|
| subjects affected / exposed | 0 / 318 (0.00%) | 1 / 289 (0.35%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Infections and infestations | | | |
| Appendicitis | | | |
| subjects affected / exposed | 1 / 318 (0.31%) | 0 / 289 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Bronchiolitis | | | |
| subjects affected / exposed | 1 / 318 (0.31%) | 1 / 289 (0.35%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Lower respiratory tract infection | | | |
| subjects affected / exposed | 1 / 318 (0.31%) | 0 / 289 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Pyelonephritis | | | |
| subjects affected / exposed | 0 / 318 (0.00%) | 1 / 289 (0.35%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Tonsillitis | | | |
| subjects affected / exposed | 1 / 318 (0.31%) | 0 / 289 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Urinary tract infection | | | |
| subjects affected / exposed | 1 / 318 (0.31%) | 0 / 289 (0.00%) | |
| occurrences causally related to treatment / all | 0 / 1 | 0 / 0 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |
| Metabolism and nutrition disorders | | | |
| Type 1 diabetes mellitus | | | |
| subjects affected / exposed | 0 / 318 (0.00%) | 1 / 289 (0.35%) | |
| occurrences causally related to treatment / all | 0 / 0 | 0 / 1 | |
| deaths causally related to treatment / all | 0 / 0 | 0 / 0 | |

Frequency threshold for reporting non-serious adverse events: 5 %

| Non-serious adverse events | aQIV | Comparator QIV | |
|---|--------------------|--------------------|--|
| Total subjects affected by non-serious adverse events | | | |
| subjects affected / exposed | 253 / 318 (79.56%) | 210 / 289 (72.66%) | |
| Nervous system disorders | | | |
| Somnolence | | | |
| subjects affected / exposed | 74 / 318 (23.27%) | 53 / 289 (18.34%) | |
| occurrences (all) | 74 | 53 | |
| General disorders and administration site conditions | | | |
| Influenza like illness | | | |
| subjects affected / exposed | 24 / 318 (7.55%) | 30 / 289 (10.38%) | |
| occurrences (all) | 24 | 30 | |
| Injection site erythema | | | |
| subjects affected / exposed | 88 / 318 (27.67%) | 58 / 289 (20.07%) | |
| occurrences (all) | 88 | 58 | |
| Injection site haemorrhage | | | |
| subjects affected / exposed | 30 / 318 (9.43%) | 25 / 289 (8.65%) | |
| occurrences (all) | 30 | 25 | |
| Injection site induration | | | |
| subjects affected / exposed | 58 / 318 (18.24%) | 32 / 289 (11.07%) | |
| occurrences (all) | 58 | 32 | |
| Injection site pain | | | |
| subjects affected / exposed | 147 / 318 (46.23%) | 82 / 289 (28.37%) | |
| occurrences (all) | 147 | 82 | |
| Pyrexia | | | |
| subjects affected / exposed | 55 / 318 (17.30%) | 37 / 289 (12.80%) | |
| occurrences (all) | 55 | 37 | |
| Gastrointestinal disorders | | | |
| Diarrhoea | | | |
| subjects affected / exposed | 33 / 318 (10.38%) | 20 / 289 (6.92%) | |
| occurrences (all) | 33 | 20 | |
| Vomiting | | | |
| subjects affected / exposed | 19 / 318 (5.97%) | 11 / 289 (3.81%) | |
| occurrences (all) | 19 | 11 | |
| Psychiatric disorders | | | |

| | | | |
|---|-------------------------|-------------------------|--|
| Eating disorder subjects affected / exposed occurrences (all) | 55 / 318 (17.30%) 55 | 30 / 289 (10.38%) 30 | |
| Irritability subjects affected / exposed occurrences (all) | 83 / 318 (26.10%) 83 | 49 / 289 (16.96%) 49 | |
| Infections and infestations | | | |
| Otitis media subjects affected / exposed occurrences (all) | 37 / 318 (11.64%) 37 | 34 / 289 (11.76%) 34 | |
| Pharyngitis streptococcal subjects affected / exposed occurrences (all) | 16 / 318 (5.03%) 16 | 6 / 289 (2.08%) 6 | |
| Upper respiratory tract infection subjects affected / exposed occurrences (all) | 32 / 318 (10.06%) 32 | 38 / 289 (13.15%) 38 | |

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

| Date | Amendment |
|-----------------|--|
| 29 July 2014 | <ul style="list-style-type: none">- The immunogenicity endpoints were updated to include secondary immunogenicity endpoints at Day 181. The percentage of subjects achieving seroconversion and HI titer $\geq 1:40$ at Day 181 were included as additional secondary immunogenicity endpoints.- Secondary objectives were updated to clarify that the 2 vaccine groups would be compared with regard to antibody response to homologous and heterologous influenza strains for the following endpoints: GMT, GMR (Day 22:Day 1), percentage of subjects achieving seroconversion, and percentage of subjects achieving HI titer $\geq 1:40$. |
| 27 October 2014 | <ul style="list-style-type: none">- Text was added throughout the protocol to provide clarity on what information regarding influenza high risk status should be collected and the analysis to be conducted using this data.- The Medically Attended Adverse Events section was added to provide clarity on definition of medically attended AEs, where and when they should be recorded. |

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported